Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

NCT00538902 is registered in ClinicalTrials.gov with Abbott as lead sponsor.

NCT NCT00538902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00538902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Randomized, Phase 2/3, Double-blind, Parallel-group, Placebo-controlled Study to Assess the Safety and Efficacy of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate
Lead sponsor
Abbott
Phase
Phase 2/3
Overall status
Completed
Start date
August 31, 2007
Completion date
December 31, 2009
Enrollment
302 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis